# Understanding the Speeding Therapy Access Today Act

This bill creates a new government office dedicated to helping rare disease treatments get developed and approved faster. If you or someone you know has a rare disease, this could eventually make it easier to access new therapies. Even if you don't have a rare disease yourself, this bill affects how the FDA operates and how insurance companies think about covering experimental treatments.

The core idea is straightforward: rare diseases are so uncommon that drug companies often don't develop treatments for them because there aren't enough patients to make it profitable. The bill establishes a new "Intercenter Institute on Rare Diseases and Conditions" within the FDA—basically a dedicated team focused entirely on rare disease problems. This institute will coordinate across different FDA departments, work with patients and doctors to understand what's needed, and figure out creative solutions to regulatory roadblocks. For example, if testing a new therapy for a disease affecting only 500 people worldwide requires the same expensive animal testing as a drug for millions of people, that's economically impossible. This institute will explore whether those requirements can be adjusted for ultra-rare situations.

The bill also creates an advisory committee that includes patients, caregivers, and rare disease experts who will advise the FDA on how to make the approval process work better for these treatments. Additionally, it establishes a program where drug companies can get early feedback from insurance companies (including Medicare and Medicaid) about what kind of evidence they'll need to cover a new rare disease therapy. This helps developers design their studies to produce the right data from the start, rather than discovering too late that insurers won't pay for the treatment. The bill also directs the government to issue guidance to state Medicaid programs when new rare disease drugs are approved, helping them understand the treatments and make coverage decisions.

Speeding Therapy Access Today Act of 2021

Bilirakis, Gus M.

Speeding Therapy Access Today Act of 2021 This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases. The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies). The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations. The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.